AngioDynamics (NASDAQ:ANGO) Updates FY25 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY25 earnings guidance on Thursday. The company provided earnings per share guidance of ($0.42)-($0.38) for the period, compared to the consensus earnings per share estimate of ($0.41). The company issued revenue guidance of $282-288 million, compared to the consensus revenue estimate of $284.37 million. AngioDynamics also updated its FY 2025 guidance to -0.420–0.380 EPS.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ANGO. HC Wainwright reissued a buy rating and issued a $14.00 price target on shares of AngioDynamics in a research report on Friday, September 20th. Canaccord Genuity Group dropped their price objective on shares of AngioDynamics from $18.00 to $13.00 and set a buy rating for the company in a report on Wednesday, July 17th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $12.25.

AngioDynamics Price Performance

Shares of AngioDynamics stock opened at $7.65 on Thursday. The firm has a market cap of $306.42 million, a P/E ratio of -1.58 and a beta of 0.65. The firm has a 50 day simple moving average of $7.53 and a 200 day simple moving average of $6.62. AngioDynamics has a fifty-two week low of $5.26 and a fifty-two week high of $8.25.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The business had revenue of $71.00 million during the quarter, compared to analyst estimates of $70.86 million. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. AngioDynamics’s revenue for the quarter was down 22.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.02 earnings per share. On average, sell-side analysts expect that AngioDynamics will post -0.41 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.